Equity Field Notes from temporal sources

[DanWebzster]

AKAO FDA approved their antibiotic for the Urinary Tract Infection indication, but did not approve its use in the bloodstream infections indication.

As a result the stock dropped more than 25%.

Their cash runway will barely get them to the end of 2018.

OTOH, their antibiotic will be priced at 1000 per day for a minimum 10-day course. If their launch puts them on a course to acheive 10%
market share, their revs could equal $450mn. If they trade at 3xRevs, that would be $30/share.

AKAO maintains that it has a go-it-alone strategy, but that might just be a negotiating ploy.

I will keep this on my watch list and watch scripts.